Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants-Reference-Cited by-同舟云学术

Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants

Published:2015-05-04 Issue:6 Volume:125 Page:2532-2546
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Hanson Melissa C.,Crespo Monica P.,Abraham Wuhbet,Moynihan Kelly D.,Szeto Gregory L.,Chen Stephanie H.,Melo Mariane B.,Mueller Stefanie,Irvine Darrell J.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference94 articles.

1. Accelerating Next-Generation Vaccine Development for Global Disease Prevention

2. Vaccines for the twenty-first century society

3. Vaccine Adjuvants: Putting Innate Immunity to Work

4. Key roles of adjuvants in modern vaccines

5. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2D Differential Metallic Immunopotentiators Drive High Diversity and Capability of Antigen‐specific Immunity Against Tumor;Advanced Science;2024-09-03

2. Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy;Materials Today;2024-09

3. Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer;2024-08-30

4. STING Agonist Induced Innate Immune Responses Drive Anti-Respiratory Virus Activity In Vitro with Limited Antiviral Efficacy In Vivo;ACS Infectious Diseases;2024-08-29

5. Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity;npj Vaccines;2024-08-17